Arcturus Therapeutics (ARCT) Q4 2024 Annual Earnings
ARCT·Reported March 6, 2025·After market close
Arcturus Therapeutics reported Q4 2024 revenue of $21.0M, missed analyst consensus of $44.6M by $23.6M. Diluted EPS came in at $-1.11, missed the $-0.33 consensus by $0.78.
Revenue
$21.0Mmissed by $23.6M
Consensus: $44.6MDiluted EPS
$-1.11missed by $0.78
Consensus: $-0.33
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Arcturus Therapeutics's Q4 2024 earnings report.
Arcturus Therapeutics (ARCT) reported Q4 2024 earnings on March 6, 2025 after market close.
Arcturus Therapeutics reported revenue of $21.0M and diluted EPS of $-1.11 for Q4 2024.
Revenue missed the consensus estimate of $44.6M by $23.6M. EPS missed the consensus estimate of $-0.33 by $0.78.
You can read the 10-K periodic report (0000950170-25-034787) directly on SEC EDGAR. The filing index links above go to sec.gov.